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Abstract
Definition and classification: Pulmonary hypertension (PH) is a group of life-threatening progressive diseases of 
various genesis, characterized by a progressive increase in arterial pressure (AP) in the pulmonary artery (PA), the 
remodeling of pulmonary vessels, which leads to an increase in pulmonary vascular resistance and pulmonary arterial 
pressure and more often leads to right ventricular heart failure and premature death. Pulmonary hypertension is clinical-
ly divided into five groups: patients in the first group have idiopathic pulmonary arterial hypertension (IPAH), whereas 
in patients of other groups secondary PH associated with cardiopulmonary or other systemic diseases is observed. The 
development of secondary LH is caused by congenital heart defects, collagenoses, presence of thrombus in the pulmo-
nary artery, prolonged high pressure in the left atrium, hypoxemia, chronic obstructive pulmonary diseases (COPDs). 
In case of secondary PH, thrombosis and other changes in the pulmonary veins occur.
Ways of pharmacological correction of pulmonary hypertension: Over the last decade pharmacotherapy of PH has 
been developing rapidly, and the introduction of modern methods of treatment, especially for primary PAH, has led to pos-
itive results. However, despite the progress in treatment, the functional limitations and survival of patients remain unsatis-
factory. Currently, there are two levels of treatment for pulmonary hypertension: primary and specific pathogenetic thera-
pies. Primary therapy is aimed at the main cause of PH. It also includes supportive therapy. Pathogenetic therapy includes 
prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors. Tactics of therapy can be established on 
the basis of either clinical classification, or functional class. Prostanoids are a promising group of drugs for the treatment of 
pulmonary arterial hypertension (PAH), since they possess not only vasodilating, but also antiplatelet and antiproliferative 
actions. Therefore, it seems logical to use prostacyclin and its analogs to treat patients with various forms of PAH.
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Definition and classification
Pulmonary arterial hypertension (PAH) is defined as a 
chronic increase in mean and systolic blood pressure in 
the pulmonary artery (it exceeds 25 mmHg at rest and 
more than 30 mmHg under physical exertion). The di-
sease is characterized by a progressive increase in pul-
monary vascular resistance and hypertrophy of the right 
ventricle of the heart.
Pulmonary hypertension is clinically divided into five 
groups (Table 1): patients in the first group have idiopathic 
pulmonary arterial hypertension (IPAH), whereas in other 
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Table 1. Classification of pulmonary hypertension
1. Pulmonary hypertension
1.1. Idiopathic
1.2. Hereditary
1.2.1 Mutation of the type 2 receptor gene to the bone morphogenesis protein (BMPR2);
1.2.2 Mutation of the activin-like kinase-1 gene (ALK-1) with and without hereditary hemorrhagic telangiectasia;
1.2.3 Unknown mutations
1.3. Pulmonary hypertension caused by medicinal and toxic effects
1.4. Pulmonary hypertension associated with:
1.4.1 Connective tissue diseases;
1.4.2 HIV infection;
1.4.3 Portal hypertension;
1.4.4 Congenital heart disease;
1.4.5 Schistomatosis;
1.4.6 Chronic hemolytic anemia
1.5. Persistent pulmonary hypertension of newborns
2. Pulmonary hypertension due to lesion of the left chambers of the heart
2.1. Systolic dysfunction of the left ventricle
2.2. Diastolic dysfunction of the left ventricle
2.3. Defects of the valves of the left heart
3. Pulmonary hypertension due to the pathology of the respiratory system and/or hypoxia
3.1. Chronic obstructive pulmonary disease (COPD)
3.2. Interstitial lung diseases
3.3. Other pulmonary diseases with mixed restrictive and obstructive components
3.4. Respiratory disturbances during sleep
3.5. Alveolar hyperventilation
3.6. High-altitude pulmonary hypertension
3.7. Malformations of the respiratory system
4. Chronic thromboembolic pulmonary hypertension
5. Pulmonary hypertension due to unclear multifactorial mechanisms
5.1. Diseases of the blood: myeloproliferative diseases, splenectomy
5.2. Systemic diseases: sarcoidosis, Langerhans histiocytosis, histiocytosis X, lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3. Metabolic diseases: glycogen accumulation disease, Gaucher’s disease, thyroid disease
5.4. Others: tumor obstruction, pulmonary lymphangiomatosis, as a result of pulmonary artery compression, adenopathy, fibrosing 
mediastenitis, chronic renal failure in patients on hemodialysis.
patients, secondary PH is associated with cardiopulmo-
nary or other systemic diseases (Simonneau et al. 2009).
Idiopathic PAH occurs in the absence of known risk 
factors and is the most common form of the disease (Galiè 
et al. 2009d, Badesch et al. 2010).
Figures 1 and 2 show the distribution of additional 
sub-categories of PAH that include the family form (now 
called hereditary), the form induced by drugs and toxins, 
and forms associated with connective tissue diseases, 
congenital heart diseases, HIV infection, portal hyperten-
sion and other conditions (Badesch et al. 2010). 
Based on hemodynamic parameters, pulmonary hyper-
tension is classified into two groups.
Pre-capillary form of pulmonary hypertension is 
characterized by increased pressure (and hence resistan-
ce) in small arterial vessels of the pulmonary trunk sys-
tem. The causes of precapillary hypertension are spasm 
of arterioles and embolism of the branches of the pulmo-
nary artery.
The postcapillary form of pulmonary hypertension is 
caused by a decrease in the outflow of blood through the 
pulmonary vein system. It is characterized by congestion 
in the lungs, arising and intensifying along with compres-
sion of the pulmonary veins with a tumor, connective tis-
sue scars, as well as with various diseases accompanied 
by left ventricular heart failure (mitral stenosis, hyper-
tension, myocardial infarction, cardiosclerosis, etc.). It 
should be noted that the postcapillary form may compli-
cate the precapillary form, and the precapillary form may 
complicate the postcapillary form.
Ways of pharmacological 
correction of pulmonary 
hypertension
Over the last decade, pharmacological correction of pul-
monary hypertension has been developing rapidly, and the 
introduction of new treatments, especially for idiopathic 
pulmonary arterial hypertension, has improved the results 
of treatment of patients with this disease.
Growing interest of researchers in the world to the 
problem of pulmonary arterial hypertension and its phar-
macological correction is clearly shown in Figure 3. An 
analysis of the publication activity of authors in a retrie-
val system, PubMed, on the problem of pharmacological 
correction of pulmonary hypertension made it possible to 
establish a two-time increase in the number of publicati-
ons for the period from 2007 to 2017.
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Figure 2. Classification of associated PAH in accordance with the data of the World Health Organization
1 – collagen vascular diseases/connective tissue diseases; 2 – portal hypertension; 3 – drug-induced/toxin-induced; 4  – HIV-in-
duced; 5 – other reasons; 6 – congenital heart diseases
Figure 1. Classification of the first group of LAS in accordance with the data of the World Health Organization
1 – Idiopathic pulmonary arterial hypertension (IPAH); 2 – associated pulmonary arterial hypertension (APAH); 3 – familial pul-
monary arterial hypertension (FPAH); 4 – pulmonary veno-occlusive disease (PVOD); 5 – pulmonary capillary hemangiomatosis 
(PCHA)
A meta-analysis of 23 randomized controlled trials 
showed a 43% reduction in mortality and 61% reduction 
in admission rates for patients with idiopathic pulmonary 
arterial hypertension who received specific therapy com-
pared with placebo (Galiè et al. 2009b).
Nevertheless, for a sufficiently large sample of patients, 
a very poor prognosis and a rapid deterioration of their 
condition are still characteristic, in connection with the 
development of heart failure leading to a fatal outcome.
For these reasons, early detection and treatment of pul-
monary hypertension is crucial. Treatment begins with a 
baseline assessment of the severity of the disease, which 
is important, since the response to therapy will be evalua-
ted as a change from baseline indicators prior  to pharma-
cological correction. Table 2 shows the functional classi-
fication of pulmonary hypertension according to WHO. 
Functional disorder and hemodynamic disorder are the 
key determinants of the severity of the disease.
Echocardiography (EchoCG) is the most informative 
noninvasive method for diagnosing pulmonary hyperten-
sion (PH). It allows not only to calculate the pressure in 
the pulmonary artery (PLA) and determine a degree of 
Research Result: Pharmacology and Clinical Pharmacology 4(2): 59–76 
Korokina LV et al.: Principles of  pharmacological correction ...62
Figure 3. Indicators of the authors’ publication activity in the PubMed information retrieval system on the problem of pharmaco-
logical correction of pulmonary hypertension from 2000 to 2017
Table 2. Functional classification of pulmonary hypertension in accordance with the World Health Organization (WHO)
I functional class
Patients with LH without restriction of physical activity. Normal physical activity does not lead to dyspnoea, fatigue, chest pain and syncope
II functional class
Patients with LH and a slight restriction in the physical activity. At rest there are no symptoms. Normal physical activity causes shortness of 
breath, fatigue, chest pain or syncope
III functional class
Patients with LH and a significant restriction of physical activity. At rest they feel comfortable. Physical activity is lower than usual, causing 
significant shortness of breath or fatigue, chest pain or syncope in patients
IV functional class
Patients with LH who can not perform any physical activity without the appearance of symptoms. Patients have symptoms of right-sided 
heart failure. Shortness of breath and weakness are noted at rest. Discomfort increases with any physical activity
its increase, but also to carry out a differential-diagnostic 
search. In addition, the complex EchoCG makes it pos-
sible to evaluate the structural and functional state of the 
heart and the prognostic parameters of PH, including: the 
presence of effusion in the pericardial cavity, the indexed 
area of the right atrium (RA), the degree of displacement 
of the interventricular septum into the cavity of the left 
ventricle (LV) in the diastole diastolic eccentricity index), 
tricuspid annular plane systolic excursion (TAPSE,), pul-
monary vascular resistance (PVR) and myocardial func-
tion index (Tei index)
To date, the pathogenesis of pulmonary hypertension 
is poorly understood, but includes pathological changes 
in the intima, media, and adventitial layers of the vascular 
wall. Both vascular endothelial and smooth muscle cells 
in the disease are characterized by abnormal growth, with 
excessive cell proliferation and resistance to apoptosis. 
These anomalies in resident vascular cells, combined with 
inflammation, excessive vasoconstriction and thrombosis 
in situ, contribute to a physical narrowing of the distal 
pulmonary arterioles. This narrowing causes a sharp in-
crease in the resistance of the vessels of the lungs, which 
leads to a chronic and progressive increase in arterial 
pressure in the pulmonary artery.
The therapeutic targets for the treatment of pulmonary 
hypertension are goals aimed at correcting the metabol-
ic pathways of prostacyclin, endothelin, or nitric oxide 
(NO). Reversion or reduction of vasoconstriction, pro-
liferation of vascular endothelial cells, proliferation of 
smooth muscle cells and reduction in the degree of en-
dothelial dysfunction are considered effective (Boutet et 
al. 2009). For example, as is known, prostacyclins are 
powerful vasodilators that can also inhibit the growth of 
smooth muscle vessels. PAH is associated with reduced 
levels of prostacyclin in the pulmonary region as a result 
of insufficient expression of endothelial prostacyclin syn-
thase. Endothelin receptor antagonists (ERAs) block the 
action of endothelin, a potent endogenous vasoconstric-
tor and mitogen, on the receptors of smooth muscle cells. 
Phosphodiesterase type 5 inhibitors (PDE-5) facilitate va-
sodilation by stimulating the activity of the nitric oxide 
pathway by inhibiting the degradation of cGMP, a second 
messenger that causes relaxation of smooth muscle ves-
sels. New developed treatment methods which are being 
currently developed are aimed at these and additional 
ways (Fig. 4). 
Drugs currently used in the treatment of pulmonary hy-
pertension in the United States or in the European Union 
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(EU) include PDE-5 inhibitors: sildenafil (Revatio) and 
tadalafil (Adcirca), and selective endothelin-1A antago-
nist ambrisentan [Leteris (United States)/Volibris (inter-
national)]. Patients with later stages of the disease are 
often treated with prostacyclin or prostacyclin analogs, 
such as iloprost or treprostinil, administered in the form 
of several daily inhalations, epoprostenol or treprostinil 
(Remodulin) as continuous intravenous infusions. Inhala-
tion nitric oxide is permitted for the neonatal form of the 
PAH-resistant pulmonary hypertension of the newborn.
In general, there are 2 levels of pharmacological cor-
rection of pulmonary hypertension – primary therapy and 
specific therapy.
Primary pathogenetic therapy is aimed at correcting the 
underlying cause of pulmonary hypertension. It also in-
cludes supportive therapy, including adequate oxygen the-
rapy, diuretics and anticoagulants, which should be inclu-
ded in the therapy of all patients with PAH. Pathogenetic 
therapy includes prostanoids, endothelin receptor antago-
nists, and phosphodiesterase-5 inhibitors. These drugs are 
used in pharmacotherapy of all forms that affect several 
pathogenetic mechanisms of pulmonary arterial hyperten-
sion. Atrial septostomy and pulmonary transplantation are 
indicated for patients who are not amenable to drug treat-
ment. Tactics of therapy can be established on the basis of 
both clinical classification and functional class.
Oxygen
Oxygen is the main element that participates in all energy 
processes of the body, providing it with normal vital acti-
vity. Oxygen is indicated for all forms of pulmonary hy-
pertension. Under its action, hypoxia and, as a consequen-
ce, vasoconstriction (constriction) of vessels of a small 
circle decrease.
Oxygen therapy is one of the most important life-sa-
ving methods of treating pulmonary hypertension. It is 
based on breathing pure oxygen and allows to compensa-
te for oxygen deficiency at the cellular level. Unlike most 
modern medical methods, oxygen therapy is completely 
safe, since oxygen has practically no contraindications 
and does not cause allergic reactions. It should be noted 
that patients with pulmonary hypertension need a long, 
sometimes lifelong, oxygen therapy. Oxygen is adminis-
tered to patients by inhalation.
Indications for oxygen therapy are usually establis-
hed with the value of arterial oxygen pressure (PaO2) 
less than 60 mm Hg. Continuous administration of oxy-
gen is the cornerstone of therapy for patients with group 
3 pulmonary hypertension , but it should also be consi-
dered in all patients with pulmonary hypertension com-
bined with hypoxemia at rest, during exercise and/or at 
night. Indeed, oxygen therapy is the only treatment with a 
Figure 4. Mechanisms of the pathogenesis of pulmonary hypertension as targets for its pharmacological correction. Note: Pre-pro-
ET is an endothelin precursor, ETA is an endothelin type A receptor, an ETB is an endothelin type B receptor, cGMP is a cyclic 
guanidine monophosphate, cAMP is a cyclic adenosine phosphate, PgI2 is a prostaglandin I2.
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proven reduction in mortality in some patients with PAH, 
as demonstrated by two large randomized clinical trials 
in which patients with chronic obstructive pulmonary di-
sease (COPD), the most common cause of development 
of PAH, were studied (NOTT 1980, MRC 1981). In con-
trast, there is no randomized data to suggest that long-
term oxygen therapy is useful for patients with idiopathic 
pulmonary hypertension, although it has been demonstra-
ted that pulmonary vascular resistance was reduced in pa-
tients when oxygen was administered (Galiè et al. 2009a)
Oxygen is usually administered through the nasal can-
nula, facial mask or Venturi mask.
Diuretics
Diuretics are used in case of decompensated heart failure 
for pharmacological correction of fluid retention, reduc-
tion of hepatic overload and peripheral edema in pulmo-
nary hypertension (Cohn 2001).
The hemodynamic effects of diuretics include a re-
duction in right ventricular preload and the tension of its 
walls; a decrease in central venous pressure; a decrease in 
the degree of tricuspid regurgitation and an increase in the 
stroke volume of the right ventricle ejected into the pul-
monary circuit; reduction in the deflection of the interven-
tricular septum toward the left ventricle and improvement 
in filling of the left ventricle; and an increased cardiac 
output (Hosenpud and Greenberg 2007).
Diuretics are especially indicated in patients with 
groups 2 and 3 pulmonary hypertension. There is cur-
rently no information on randomized controlled clinical 
studies on the use of diuretics in pulmonary arterial hy-
pertension; however, clinical experience also shows the 
symptomatic benefits from using diuretics when decom-
pensated right heart failure occurs. It should be borne in 
mind that diuretics should be used with caution in order 
to avoid a reduction in cardiac output, arrhythmias caused 
by hypokalemia, and metabolic alkalosis. The most com-
monly used loop diuretic is furosemide, usually used in an 
initial dose of 20-40 mg per day.
Anticoagulants
Patients with pulmonary hypertension are at increased 
risk of intrapulmonary thrombosis and thromboembolism 
due to decreased pulmonary blood flow, enlarged right 
heart, venous stasis and sedentary lifestyles. These risk 
factors and the understanding that even a small blood clot 
can cause hemodynamic deterioration in a patient with 
compromised pulmonary vessels is the rationale for pre-
scribing oral anticoagulant therapy for pulmonary hyper-
tension. It is generally recognized that anticoagulants are 
indicated in patients with idiopathic pulmonary hyperten-
sion, hereditary PAH and drug-induced PAH (Barst et al. 
2009, Galiè et al. 2009a, McLaughlin et al. 2009)
Most of the data was obtained in the study of patients 
with idiopathic pulmonary hypertension (Kawut et al. 
2005, Barst et al. 2009). In a systematic analysis of seven 
studies evaluating the effect of warfarin in patients with 
group 1 pulmonary hypertension, five studies showed a 
reduction in the risk of intrapulmonary thrombosis and 
thromboembolism (Johnson et al. 2006).
In patients with hereditary PAH and drug-induced 
LAH, the benefits of anticoagulant therapy were evalua-
ted taking into account the risk of bleeding. The drug of 
choice for oral anticoagulant therapy for pulmonary hy-
pertension is warfarin.
Physical exercise
Physical exercise is indicated in patients with pulmonary 
hypertension. (Mereles et al. 2006, de Man et al. 2009). 
In randomized controlled clinical trials, improvement in 
physical performance was demonstrated in patients with 
PAH who performed a set of physical exercises (Mereles 
et al., 2006). Exercise improves the functional parame-
ters of the bronchopulmonary system and peak oxygen 
consumption, not appreciably affecting hemodynamic pa-
rameters (Mereles et al. 2006). Moreover, patients with 
severe PAH have skeletal muscle hypertrophy, which can 
be corrected by a physical rehabilitation program (Galiè 
et al. 2009a). Thus, skeletal muscle training can play a 
role in the treatment of patients with PAH.
Pathogenetic therapy
Tactics of therapy can be established on the basis of both 
clinical classification and functional class. Specific patho-
genetic therapy is performed in patients with functional 
class II, III or IV PAH, despite adequate primary therapy 
(Badesch et al. 2007, Barst et al. 2009). These drugs are 
used in pharmacotherapy of all forms and affect several pa-
thogenetic mechanisms of pulmonary arterial hypertension.
The characteristics of drugs used to treat pulmonary 
hypertension is presented in Table 3.
Before starting therapy, it is necessary to assess he-
modynamic parameters in patients with PAH. Patients 
with PAH 1 group should undergo a test for vasoreac-
tivity with intravenous administration of adenosine, 
epoprostenol or inhalation of nitric oxide NO (Barst et 
al. 2009). Patients with a positive test for vasoreactiv-
ity need the prescription for oral therapy with calcium 
channel blockers. In contrast, patients with a negative 
vasoreactivity test need therapy with a prostanoid endo-
thelin receptor antagonist or a type 5 phosphodiesterase 
inhibitor. A combination therapy is indicated in cases 
of refractoriness to ongoing pharmacotherapy. In case 
of ineffective pharmacotherapy, the issue of lung trans-
plantation or shunting in atrial septostomy is considered 
(Keogh et al. 2009). 
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Calcium channel blockers
The rationale for using vasodilators is their influence on 
pathogenetic mechanisms of a progressive increase in 
pulmonary vascular resistance and hypertrophy of the 
right ventricle of the heart in PAH.
However, only a small proportion of patients on the 
background of ongoing vasodilator therapy demonstrate 
a positive response to the vasoreactivity test. In patients 
taking nifedipine or diltiazem, the functional state of the 
bronchopulmonary system and hemodynamic parameters 
improve, and life expectancy also increases (Rich et al. 
1992, Humbert et al. 2004a, Sitbon et al. 2005). Effective 
doses of calcium channel blockers used in different forms 
of PAH are 120-240 mg for nifedipine, and 240-720 mg 
for diltiazem. The therapy should be started with a mini-
mum therapeutic dose of long-acting nifedipine (30 mg/
day) or diltiazem (120 mg/day), which should be brought 
up to the maximum therapeutic dose. It is recommended 
to prescribe sustained-release preparations of nifedipine 
and diltiazem, since they minimize the adverse effects of 
therapy, especially systemic hypotension and orthostatic 
states. Patients who receive CCB therapy should undergo 
a controlled pharmacotherapy and dose adjustment after 
3-6 months of treatment.
Endothelin receptor antagonists
Endothelin-1 is a potent vasoconstrictor and mitogenic 
factor for vascular smooth muscle cells, fibroblasts and 
cardiomyocytes. High concentrations of endothelin-1 
were detected in the lungs of patients with PAH (Chan-
nick et al. 2004). In smooth muscle cells of pulmonary 
vessels and in endothelial cells, there are two different 
types of receptors: endothelin-A and endothelin-B re-
ceptors. Despite the differences in their activity towards 
different receptors, the efficacy of double and selective 
endothelin receptor antagonists seems to be comparable.
Bozanthan is the first oral non-selective preparation of 
the class of endothelin-A and -B receptor blockers. Bozen-
tan therapy was studied in patients with PH in 5 randomized 
controlled trials that demonstrated increased exercise toler-
ance, reduced functional class of PLG, improved hemody-
namic parameters, echocardiography and dopplerographic 
indices, and an increased time to clinical deterioration.
The drug was effective in patients with pulmonary hyper-
tension 1 group with II, III and IV functional class of PAH.
The initial therapeutic dose was 62.5 mg twice daily 
and was increased to 125 mg twice daily for 4 weeks. 
Long-term observational studies have confirmed the 
long-term effect of bosentan therapy. In 10% of patients, 
a dose-dependent increase in hepatic transaminases de-
velops, which is completely reversible with a decrease in 
the dose of bosentan or its withdrawal. Therefore, patients 
receiving bosentan therapy should at least once a month 
take a blood test that determines the function of the liver.
Sitaxentan is a selective oral endothelin-A receptor 
blocker. Its efficacy was studied in two randomized con-
trolled trials in patients with LH II/III FC according to the 
WHO. Depending on the etiology of LH, the group in-
cluded patients with ILH, PLH, associated with systemic 
connective tissue diseases or congenital heart diseases. 
These studies demonstrated an increase in physical ac-
tivity tolerance and improvement in hemodynamic para-
meters against the background of sitaxentan treatment. In 
an open observational study, the stability of the effect of 
sitaxentane treatment throughout the year was noted. The 
frequency of changes in functional hepatic tests was 3-5% 
for the approved dosage of sitaxentan of 100 mg/day; it 
was completely reversible. However, this side effect of 
sitaxentan requires monthly monitoring of liver samples.
Ambrisentan is a non-sulfonamide selective endot-
helin-A receptor antagonist, referring to preparations of 
propanoic acid. Ambreased therapy was studied in one pi-
lot and two large randomized controlled trials that demon-
strated a reduction in the clinical symptoms of PLH, incre-
ased exercise tolerance, improved hemodynamics, and an 
increased time to clinical deterioration. In an open obser-
Table 3. Characteristics of drugs used to treat pulmonary hypertension
Drug Route of administration Dose
Calcium channel blockers
Nifedipine Orally 120-240 mg/day
Diltiazem Orally 240-720 mg/day
Amlodipine Orally 20 mg/day
Prostanoids
Epoprostenol Intravenously 1-40 ng/kg/min
Treprostinil Subcutaneously/intravenously 2-80 ng/kg/min
Iloprost Inhalation 2.5-5 μg, 6-9 times/day
Endothelin receptor antagonists
Bozentan Orally 62,5-125 mcg, 2 times/day
Ambrisentan Orally 5-10 mg/day
Inhibitors of phosphodiesterase-5
Sildenafil Orally 20 мг, 3 times/day
Tadalafil Orally 5-40 mg/day
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vational study, the stability of the effect of ambrisental tre-
atment throughout the year was noted (Galiè et al. 2008b, 
Oudiz et al. 2009). Ambrisentan is also approved for the 
treatment of patients of FC-II according to the WHO. The 
dose of 5 mg/day can be increased to 10 mg/day with the 
initial good tolerability profile of the drug. The frequency 
of changes in functional hepatic tests is 0.8-3% of cases. 
Nevertheless, all patients taking ambrisentine should have 
their liver tests monitored on a monthly basis.
Phosphodiesterase type 5 (PDE-5) 
inhibitors
The mechanism of action of PDE-5 inhibitors is associated 
with an effect of nitric oxideNO-cyclic guanosine monop-
hosphate on the system. The oppression of destruction of 
the latter leads to a sharp increase in its concentration in cells 
in which the main form of phosphodiesterases is precisely 
PDE-5. In smooth muscle cells of blood vessels, including 
pulmonary tissue, this causes relaxation and vasodilation.
Sildenafil is an oral potent selective phosphodiestera-
se-5 inhibitor that realizes its pharmacological effect by 
increasing the concentration of cGMP in the cell. A num-
ber of uncontrolled studies have described the benefici-
al effect of sildenafil therapy in patients with ILH, PLH 
associated with systemic connective tissue diseases and 
congenital heart diseases, and chronic thromboembo-
lic PH (Galiè et al. 2005, Pepke-Zaba et al. 2008). The 
most significant was a randomized controlled trial with 
278 patients with PLH who received sildenafil therapy at 
dosages of 20, 40 and 80 mg 3 times a day. It was used 
to confirm the positive effect of sildenafil on exercise to-
lerance, symptom severity and hemodynamics. Despite 
the approved dose of sildenafil of 20 mg 3 times a day, 
prolonged maintenance of the effect of therapy during the 
year was observed only with the use of sildenafil in a dose 
of 80 mg 3 times a day (Galiè et al. 2005). Typically, in 
clinical practice, titration of the dosage of sildenafil over 
20 mg 3 times a day (usually 40-80 mg 3 times a day) is 
necessary. Most undesirable effects of sildenafil are mild 
or moderate and are most often due to vasodilation.
Tadalafil is an oral single-dose preparation, a selective 
phosphodiesterase-5 inhibitor, currently approved for the 
treatment of erectile dysfunction. The most important 
randomized controlled clinical trial included 406 patients 
with PGH who received 5, 10, 20 or 40 mg of tadalafil 
per day. It showed a beneficial effect on exercise toleran-
ce, symptom severity, hemodynamics, as well as time to 
deterioration of LH course when using the highest dosage 
(Galiè et al. 2009c).
Combination therapy
It is suggested that a combination of pharmacological 
agents with different mechanisms of action may have an 
additive effect or may cause the same effect at lower doses 
of each component. Currently, a comprehensive evaluati-
on of the effecacy of combination therapy is conducted in 
clinical trials.
In a series of clinical studies, the effecacy and safe-
ty of various combinations were demonstrated. In the 
STEP-1 study, 12-week therapy with inhaling iloprost 
in combination with bosentan resulted in a pronounced 
increase in the distance in T6MX. After inhalation of 
iloprost, its increase was +26 m (p=0.051). When car-
rying out T6MX prior to inhalation, an increase in dis-
tance compared with placebo was +19m, which was 
unreliable. After 12 weeks of therapy with iloprost, no 
significant changes in hemodynamic parameters were 
noted, but the time to clinical deterioration was im-
proved compared to that in the placebo group (0 events 
versus 5 in the placebo group) (Hoeper et al. 2003). In 
contrast, a COMBI study evaluating the potential of the 
combination therapy with iloprost and bosentan was ter-
minated prematurely due to a lack of effect on exercise 
tolerance and time to clinical deterioration. It is impor-
tant to note the peculiarities in the joint use of drugs 
of specific PAH therapy. Thus, in the EARLY study, 
pharmacokinetic interactions between bosentan and sil-
denafil, which are respectively an inhibitor and inducer 
of cytochrome P450 isoenzymes, were studied,. When 
combined, the concentration of sildenafil decreases, and 
that of bosentan increases. But this does not affect the 
effecacy of therapy (Mathai et al. 2007).
The indication for combination therapy in patients 
with PAH is lack of a stable clinical effect. Boszen-
tan is an inducer of the cytochrome P450isoenzymes 
CYP3A4, CYP2C9. Plasma concentrations of drugs 
metabolized by these isoenzymes decrease when used 
together with bosentan. The concentration of bosentan 
increases when combined with CYP3A4 inhibitors (ke-
tonazole, ritonavir) and/or CYP2C9 inhibitors (amio-
darone, fluconazole). Therefore, bosentan is potentially 
contraindicated when administering these drugs. Bo-
sentan is considered contra-indicated when taking the 
following drugs: itraconazole, tacrolimus, sirolimus, 
carbamazepine, phenobarbital, and dapsone. The main 
pathway of sildenafil metabolism is CYP3A4 and, to 
a lesser extent, CYP2C9. CYP3A4 inducers (carbama-
zepines, phenytoin, phenobarbital, rifampicin) reduce 
the concentration of sildenafil. The concentration of the 
drug increases slightly when grapefruit juice is used - a 
weak inhibitor of CYP3A4/5. Because of the risk of 
systemic hypotension, special precaution is required 
when using a specific therapy of PAH with antihyper-
tensive drugs, such as b-adrenoblockers and ACE in-
hibitors.
There are many unresolved issues regarding combina-
tion therapy, including the choice of the optimal combina-
tion of drugs, the optimal time and method of administra-
tion. Combination therapy of different groups of PAH is 
recommended for patients who do not respond adequately 
to monotherapy (Galiè et al. 2009a)
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Surgical intervention
In extreme cases, when drug therapy does not have the 
desired effect, surgery is usually resorted to:
Atrial septostomy
Atrial septostomy involes the formation of a defect between 
the atria with the shunting of blood from right to left. Per-
cutaneous step-by-step balloon septostomy is the preferred 
technique. The basis for this intervention is an increase in 
life expectancy in patients with PAH and patients with an 
open foramen ovale. The creation of a shunt reduces the 
preload on the right ventricle, which facilitates its work 
and can increase cardiac output and improve the tolerance 
of physical exertion. Such an increase in cardiac output oc-
curs at the cost of reducing the systemic saturation of arterial 
blood; however, as a rule, the systemic transport of oxygen 
improves (Reichenberger et al. 2003). This intervention is 
usually performed on patients who have not responded to the 
maximum possible drug treatment, or as a palliative measu-
re while waiting for transplantation (Doyle et al. 2004).
Lung transplantation
In recent years, significant progress has been made in the 
drug therapy of pulmonary vascular diseases, primarily 
idiopathic pulmonary hypertension, which has made it 
possible to exclude most such patients from waiting lists 
for transplantation of lung and the cardiopulmonary com-
plex, thus significantly improving their prognosis for sur-
vival (Keogh et al. 2009). Studies show that up to 25% of 
patients with idiopathic PAH do not show any significant 
improvement in status against the background of specific 
pharmacotherapy and have a poor prognosis for survival 
(McLaughlin et al. 2002, Sitbon et al. 2002).
Lung transplantation (TL) is the only radical treatment 
for patients with irreversible pulmonary parenchyma and/
or pulmonary vascular diseases. If multicomponent thera-
py, including the use of selective pulmonary vasodilators, 
is ineffective, bilateral TH is indicated for primary pulmo-
nary arterial hypertension.
Bilateral lung or heart-lung transplantation is the pro-
cedure of choice (Keogh et al. 2009). The 3-year survival 
rate of patients who underwent transplantation of lung or 
heart and lung for idiopathic PAH is approximately 50% 
(Doyle et al. 2004, Trulock et al. 2007).
The recommendations for sending the patient for trans-
plantation evaluation are as follows:
• functional class 3-4 according to NYHA, despite the 
ongoing PAH-specific therapy;
• rapid progression of the disease;
• use of intravenous PAH-specific drugs regardless of 
the symptoms or the size of the functional class;
• confirmed or suspected diagnosis of veno-occlusive di-
sease of the lungs and/or pulmonary capillary heman-
giomatosis.
Ethical aspects of such transplantation, as well as the 
condition of living-related donors, remain the topics of 
ongoing scientific discussions. In general, the living-re-
lated (lobar) lung transplantation is considered as an 
alternative to cadaveric transplantation only for those 
recipients who, in connection with their clinical status 
and anthropometric parameters, are unlikely to wait for 
cadaveric transplantation. The “golden standard” of lung 
transplantation and the only opportunity for transplanta-
tion of the cardiovascular system is cadaveric transplan-
tation from donors with brain death. The criteria that 
determine mortality in such patients have not yet been 
determined by the moment and include a large number of 
indicators, which makes it difficult to accurately determi-
ne the time of transplanting lung to such patients (Davis 
and Garrity 2007).
Thromboendarterectomy of the lungs
Chronic thromboembolic pulmonary hypertension 
(CTERH) is an important cause of severe pulmonary 
hypertension and, as such, is associated with significant 
morbidity and mortality. The prognosis for this condition 
reflects the degree of concomitant right ventricular dys-
function with a predicted mortality rate associated with 
the severity of pulmonary hypertension.
In recent years, the epidemiology of this condition has 
been significantly revised. In the past it was considered 
a rare disease; recently it has been registered as chronic 
thromboembolic pulmonary hypertension (CTEPH) , 
complicating 3.8% of acute pulmonary embolic events 
(Galiè et al. 2009a).
Chronic thromboembolic pulmonary hypertension is 
the only cause of severe pulmonary hypertension, which 
is potentially curable without resorting to lung transplan-
tation. Pulmonary endarterectomy (PEA) is a surgical 
procedure that removes the obstructing thromboembolic 
material, which leads to a significant improvement (and in 
many cases, normalization) in hemodynamics and functi-
on of the right ventricular. This procedure requires a high 
degree of anesthesia and surgical skill combined with a 
diligent preoperative assessment of potential patients. 
Surgery is usually considered only in patients with proxi-
mal chronic thromboembolic disease, which are assessed 
using radiological studies (Rubin et al. 2006).
During the preoperative assessment of patients, sub-
jective and objective data are used to decide whether to 
perform pulmonary thromboendarterectomy in patients 
suffering from chronic thromboembolic pulmonary hy-
pertension (Dunning and McNeil 1999).
Indications for thromboendarterectomy are: FC III-IV, 
PVR≥300 dynes/sec/cm-5, the central thrombi (up to the 
segmental level) (≥50% obstruction 42 in the proximal ar-
teries according to angiopulmonography), having throm-
bosis against adequate 3-months’ anticoagulant therapy.
About 4,000 light thromboendarterectomy operations 
have been performed around the world, and good results 
have been received to improve the survival of patients, 
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to improve exercise tolerance, to improve hemodynamic 
parameters and to increase the time to clinical deteriora-
tion in patients (Keogh et al. 2009). In recent decades, 
perioperative mortality of patients who underwent throm-
boendarterectomy has decreased. According to statistics, 
of 500 patients operated on for chronic thromboembolic 
pulmonary hypertension, the mortality rate was 16% prior 
to 1990, 7% in the period between 1990 and 1999 and 4% 
in the period from 1998 to 2002 (Jamieson et al. 2003).
Algorithms of treatment
Scientists define new goals that should be pursued in the 
treatment of pulmonary hypertension, along with a re-
duction in pulmonary artery pressure (which is the focus 
of almost all drugs used to treat pulmonary hypertensi-
on at the present time). A problematic issue remains the 
algorithm for managing patients with pulmonary hyper-
tension, belonging to groups II-V according to the WHO 
classification. Obviously, for many categories of patients 
from other groups, it is impossible to automatically extra-
polate the results of clinical trials conducted on patients 
with pulmonary arterial hypertension, since a different 
pathogenesis of pulmonary hypertension and a significant 
effect of the underlying diseases causing cause this syn-
drome gives grounds to talk about significant differences 
in the necessary therapy in groups II-V and overall ma-
nagement strategy compared with group I. The experts 
can only state that the evidence base for patients with pul-
monary hypertension belonging to groups II-V remains 
meager and in most cases makes it impossible to give evi-
dence-based practical recommendations. At present, the 
number of real and potential therapeutic options for the 
treatment of this pathology has significantly increased, 
which has even reduced the need for lung transplantation 
in the developed countries of the world. It should be noted 
that a widespread use of modern drugs and methods of 
treatment is limited not only by a scanty evidence base, 
but, above all, by the high cost of appropriate drugs, sur-
geries, and diagnostic procedures. The topical therapeutic 
strategies are indicated in Table 4.
Group 1
Treatment in patients in this group is based mainly on 
specific therapy, because there are no effective primary 
treatments, especially for patients with idiopathic PAH. 
Primary therapy is possible only with PAH associated 
with other diseases. If necessary, oxygen inhalations can 
be used as symptomatic therapy for severe dyspnoea and 
hypoxia. Diuretics are administered with pulmonary hy-
pertension complicated by right ventricular failure. Dis-
aggregants and anticoagulants of indirect effect that redu-
ce blood viscosity are indicated in patients with idiopathic 
PAH (Barst et al. 2009, Galiè et al. 2009a, McLaughlin et 
al. 2009).
Group 2
Primary therapy is aimed at the main cause of PH. It also 
includes maintenance therapy, including adequate oxy-
gen therapy, diuretics and anticoagulants, which should 
be included in the therapy of all patients with PAH. Pa-
thogenetic therapy includes prostanoids, endothelin re-
ceptor antagonists, and phosphodiesterase-5 inhibitors. 
Although the optimization by means of neurohormonal 
antagonists remains the main one in the treatment of pa-
tients with systolic heart failure, attempts have been made 
to treat PAH according to the principles used in the treat-
ment of idiopathic PAH. The FIRST (Floran International 
Randomized Survival Trial) study recorded 471 patients 
with advanced heart failure to receive continuous infu-
sion of epoprostenol plus standard therapy or only stan-
dard therapy. Although hemodynamic improvement was 
recorded in patients receiving epoprostenol, the study was 
completed earlier due to a strong trend towards increased 
mortality in patients receiving epoprostenol (McLaugh-
Table 4. Therapeutic strategy according to clinical classification of PAH
Group (clinical classification) Therapeutic strategy
1 Pulmonary arterial hypertension
Specific therapy (idiopathic and hereditary forms)
Primary therapy (forms associated with other diseases)
Maintenance therapy (oxygen, oral anticoagulants, diuretics)
Surgical treatment (pulmonary and atrial transplantation, septostomy)
2 Pulmonary hypertension due to left heart disease
Primary therapy
Supportive therapy (diuretics, oxygen)
3 Pulmonary hypertension due to lung diseases and/or hypoxemia
Primary therapy
Supportive therapy (diuretics, oxygen)
Specific therapy (in some patients)
Surgical treatment (lung transplantation)
Supportive therapy (oral anticoagulant)
4 Chronic thromboembolic pulmonary hypertension
Surgical treatment
Specific therapy (in some patients)
5 Pulmonary hypertension with unclear and/or multi-factorial mechanisms
Primary therapy
Maintenance therapy (oxygen)
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lin et al. 2009). Some explanations included long-term 
adverse effects of systemic vasodilation on systolic heart 
failure and possible dangerous effects of epoprostenol on 
patients with ischemia. Basing on the results of this study, 
the chronic use of epoprostenol in patients with systolic 
heart failure is contraindicated (Badesch et al. 2010).
Group 3
Primary therapy is the main treatment for patients in this 
group. Diuretics are prescribed in the case of heart failure, 
with careful monitoring the concentration of electrolytes 
in the blood, the state of kidney function, as well as the 
volume of circulating blood and systemic blood pressure. 
Oxygenotherapy (12–15 hours per day) is indicated for 
pulmonary hypertension in patients with COPD, the le-
vel of supported saturation should be kept at least at 90% 
(Ashutosh and Dunsky 1987).
Cardiac glycosides are used for symptoms of heart fail-
ure and attacks of atrial fibrillation. Anticoagulant therapy 
is performed at the INR target level of 1.5–2.5 in the case 
of idiopathic pulmonary hypertension; in the case of asso-
ciated pulmonary hypertension, the size of the indicator is 
variable and depends on the underlying disease.
With a positive result of an acute vasoreactivity test, 
calcium channel blockers (CCBs) are prescribed, whose 
efficacy in pulmonary hypertension is proven in clinical 
trials with FC I-III.
Specific therapy for patients of group 3 should be ad-
ministered cautiously, because of disruption of gas ex-
change resulted from inhibition of hypoxic pulmonary 
vasoconstriction due to insufficient efficacy of long-term 
administration (Ghofrani et al. 2002b, Blanco et al. 2010)
Group 4
Chronic thromboembolic pulmonary hypertension 
(CTEPH) is a disease associated with the remodeling of 
LA as a result of thromboembolism of the main vessel. 
The cumulative frequency (CTEPH) is 0.1 to 9.1% in the 
first 2 years after the symptomatic episode of pulmonary 
embolism.
Optimal drug therapy (CTEPH) includes the use of 
anticoagulants and diuretics, with adequate oxygenation. 
Lifetime administration of anticoagulants is recommend-
ed even after surgery, although there is no data on the effi-
cacy and safety of new oral anticoagulants. Some nonran-
domized studies have shown an improvement in exercise 
tolerance and hemodynamics. Drug treatment (CTEPH) 
with targeted therapy may be justified in technically inop-
erable patients, or when there is an unacceptable ratio of 
surgical risk and benefit.
The standard treatment of CTEPH is pulmonary throm-
boendarterectomy (Keogh et al. 2009). When residual LH 
develops and surgery is impossible, drug treatment is re-
quireв by means of drugs used to treat pulmonary arterial 
hypertension (PAH).
Prostanoids, phosphodiesterase type 5 inhibitors, en-
dothelin receptor antagonists have been studied in a num-
ber of open studies in patients with inoperable forms of 
CTEPH. In the BENEFIT study, by the 16th week boz-
entan would contribute to a significant decrease in PVR, 
an increased cardiac output, but compared to the place-
bo, would not improve exercise tolerance according to a 
6-minute walk test. In a randomized, placebo-controlled 
CHEST-1,2 study, the efficacy and safety of riociguatum 
was demonstrated, the first representative of a new class 
of stimulants for soluble guanylate cyclase. In September 
2014, this drug was approved in Russia, including for the 
treatment of patients with inoperable CTEPH; persistent 
or recurrent CTEPH after surgery.
Group 5
Primary therapy is aimed at the main cause of PH. It also 
includes maintenance therapy, involving adequate oxy-
gen therapy, diuretics and anticoagulants, which should 
be included in the therapy of all patients with PAH. Patho-
genetic therapy includes prostanoids, endothelin receptor 
antagonists, and phosphodiesterase-5 inhibitors. These 
drugs are used simultaneously for several pathogenetic 
mechanisms of LH and are specific for PAH. Atrial sep-
tostomy and pulmonary transplantation are indicated for 
patients who are not amenable to drug treatment. Prosta-
noids are a promising group of drugs for the treatment of 
pulmonary arterial hypertension, since they have not only 
vasodilating, but also antiplatelet and antiproliferative ef-
fects. Therefore, it seems logical to use prostacyclin and 
its analogs to treat patients with various forms of PAH 
(Fisher et al. 2006).
Therapy according to the 
functional class
A therapeutic approach to pharmacotherapy of patients 
with PAH is based on the severity of the disease (Galiè 
et al. 2009a).
The functional class is a powerful predictor of out-
comes for patients suffering from PAH. Even in case of 
administering a pathogenetic therapy, patients with WHO 
FC IV have an extremely poor prognosis compared to pa-
tients with lower functional classes. According to a recent 
study conducted in France, a lower functional class (I/
II) was positively and significantly associated with better 
survival; while US REVEAL registry data suggest that 
functional class IV was not directly correlated with in-
creased mortality in patients with PAH.
After making a diagnosis, the initial measures are con-
nected with following the general recommendations and 
assigning a maintenance therapy. Patients with PAH need 
to be referred to an expert center.
All patients with PAH are indicated for having acute 
pharmacological tests (APT) to assess vasoreactivity. The 
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likelihood of a positive APT is especially high with IPAH, 
inherited PAH, PAH on the background of receiving ano-
rectics. In this category of patients, success is most likely 
when assigning anticoagulants (AC) in high doses. It is 
necessary to confirm the stability of the therapy effect in 
3-4 months.
When obtaining a negative APT, PAH patients with 
FC I-II must be assigned specific therapy with inhaling 
nitric oxide (course therapy in case of  a stable disease), 
prostaglandin E1 (course therapy in case of a stable dis-
ease), ERA (bosentan or ambrizentan) or sildenafil type 
5 (PDEI-5).
With a negative APT, patients with PAH FC III are to 
be treated by  ERA or PDEI-5, or by prostanoids. There 
are no direct comparative studies of the effectiveness 
of different types of specific therapy of PAH. Selecting 
a drug depends on a PAH form, FC, contraindications, 
availability of the drug, a route of administration, a 
side-effect profile, experience of the physician and a pa-
tient’s preferences.
Patients with FC IV are indicated for an initial com-
bination specific PAH-therapy. including two drugs: a 
combination of ERA (bosentan or ambrisent) and iloprost 
or sildenafil. If the dual specific therapy is ineffective, it 
is recommended to assign three drugs – ERA+ilopros-
t+sildenafil.
Atrial septostomy and/or transplantation are indicated 
for patients with PAH in case of an inadequate clinical 
effect of drug therapy and must be carried out only at ex-
pert centers.
Targeted therapy
For many decades, very slow progress has been observed 
in the treatment of patients with PH. The situation has 
changed significantly in recent years, due to a considera-
ble increase in the number of controlled studies. Calcium 
antagonists, anticoagulants, cardiac glycosides, oxygen 
therapy, despite the absence of appropriate clinical rando-
mized trials, currently make up a standard therapy widely 
used in patients with PH. At the same time, new groups 
of drugs have appeared, the effecacy and safety of which 
have been proved by the results of controlled studies.
This is the therapy whose goal is to reduce functional 
disorders and to prolong life (Sitbon and Galiè 2010). Tar-
geted therapy uses known prognostic indicators to assess 
the state of patients with PAH, which allows beginning a 
timely pharmacotherapy, preventing deterioration in the 
patients’ condition. A key role in this strategy is played by 
the identification of the parameters that correlate with the 
risk of deterioration and mortality. The diagnostic strategy 
for PH involves conducting a comprehensive examination 
to establish a diagnosis, to evaluate a clinical class and 
type of PH, and to assess functional and hemodynamic 
statuses of patients. It is expedient to distinguish the fol-
lowing stages of the diagnostic and differential diagnostic 
process (Sitbon and Galiè 2010).
An objective evaluation of the functional capacity of 
PH patients is necessary to assess the severity of PH and 
the dynamics of the clinical state in connection with the 
ongoing therapy. In the study of tolerance to physical 
exertion, the most commonly used test is a 6-minute walk 
and a cardiopulmonary exercise test with an assessment 
of gas exchange.
In the past, the average life expectancy with idiopathic 
PH was 3 years, in patients in FC IV <6 months; now with 
a “targeted” therapy it has improved (≈90% and ≈80% 
of patients who have been treated for arterial PH live for 
more than a year and two years, respectively). With the 
preserved reactivity of pulmonary vessels, 95% of pa-
tients live for more than 5 years. 
New classes of drugs in the 
pharmacological correction of 
pulmonary hypertension
Despite the severity of the ailment, not all forms of pul-
monary hypertension are included today in the list of 
life-threatening and chronic progressive rare (orphanic) 
diseases, leading to a reduction in the life expectancy 
of citizens or their disability. According to this list, pa-
tients are provided with medicactions. So, in the list of 
rare life-threatening diseases, there is “pulmonary arterial 
hypertension”, but patients with a diagnosis of “chronic 
thromboembolic pulmonary hypertension” (CTEPH do 
not receive appropriate medication treatment in Russia.
Therefore, the search for an “ideal” treatment conti-
nues; targeted research is conducted to identify new me-
dicinal molecules and approaches to pharmacotherapy of 
PAHs of different groups.
Below is a brief description of new classes of drugs for 
pharmacotherapy of idiopathic PAH in the future, which 
require further study.
Rho-kinase inhibitors
Rho kinase plays an important role in damaging the vas-
cular endothelium. To date, two of its isoforms are known: 
Rho-kinase1 and Rho-kinase2. The latter is expressed in 
cells of smooth muscle vessels and endothelial cells. Acti-
vation of Rho-kinase 2 is by active GTP-bound.
RhoA leads to calcium sensitization in smooth muscle 
cells via phosphorylation-mediated inhibition of myosin 
light chain phosphatase activity and, thereby, promotes 
an increase in the activity of the myosin regulatory light 
chain (Fukumoto et al. 2007).
It is known that Rho-kinase is involved in a variety of 
pathophysiological processes, among which the following 
can be distinguished: the narrowing of blood vessels, in-
cluding the development of myogenic tone and excessive 
contractility of the smooth muscles, contraction of the 
smooth muscles of the bronchi, COPD, PAH, ED, CVD 
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(Do et al. 2009). These data are confirmed by a number of 
studies. Activation of RhoA/Rh-kinase plays an important 
role in the development of ED in patients with PAH. A 
significant decrease in endothelium-dependent relaxation 
and NO levels was found, while RhoA / Rho-kinase acti-
vity increased in the pulmonary arteries of patients with 
PAH compared with those in the control group. Thus, re-
searchers linked the development of ED in PAH patients 
with inhibition of endothelial NO-synthase activity and 
activation of RhoA/Rho-kinase (Do et al., 2009).
In animal models, treatment with Rho-kinase inhibitors 
appears to improve endothelial dysfunction, enhancing the 
expression of eNOS, suppressing hypercontract and proli-
feration of smooth muscle cells (Fukumoto et al. 2007).
Fasudil is a selective inhibitor of Rho-kinase, a signa-
ling molecule involved in the implementation of the me-
chanism of contraction of smooth muscle cells in response 
to such stimulants as acetylcholine, angiotensin II, endot-
helin, noradrenaline, and serotonin. In a study in rats with 
a monocrotolin model of pulmonary hypertension, mo-
notherapy with the drug fasudil and in combination with 
sildenafil or bosentan was studied in a comparative aspect.
Fasudil reduced vasoconstriction and obstructive remo-
deling of the walls of pulmonary blood vessels and hyper-
trophy of the right heart. The combination of bosentan or 
sildenafil with fasudil was not accompanied by synergistic 
effects. These results suggest that Rho-kinase inhibitors 
may be a new therapeutic approach for treating PAH.
Stimulant and activator of soluble 
guanylate cyclase
The disruption of the production of nitric oxide plays 
an important role in the pathogenesis of PAH, which is 
due to the powerful vasodilating action, cytoprotective, 
antiproliferative, anti-inflammatory and antiaggregatio-
nal effects. Riociguat is the first representative of a new 
class of drug-stimulants of soluble guanylate cyclase. 
Riociguat proved effective in phase II of clinical trials. 
In a randomized, double-blind, placebo-controlled, Phase 
III PATENT-1 (Pulmonary Arterial Hypertension Soluble 
Guanilatcyclase-Stimulator Trial) trial, 443 patients with 
PAH symptoms were randomized to receive placebo, 
riociguat in a single dose of up to 2.5 mg (with titration 
according to tolerability up to 2.5 mg 3 times a day) or 
in a dose of up to 1.5 mg (with titration of the dose de-
pending on the tolerance to 1.5 mg 3 times a day). The 
study included patients who had not previously received 
PAH-specific therapy or who have been  already taking 
endothelin receptor antagonists or prostanoids (except for 
parenteral). By the 12th week of riociguat treatment, the 
distance of the 6-minute walk test increased on average 
by 30 m in the group of patients receiving the maximum 
single dose of 2.5 mg and decreased by an average of 6 m 
in the placebo group (the difference between the groups 
was 36 m, 95 % confidence interval 20-52 m, p<0.001). 
Riociguat improved D6MX in both patients who had not 
previously received PAH-specific therapy (+38 m), and in 
patients who had been taking endothelin receptor antago-
nists or prostanoids (+36 m). In contrast to the placebo 
group, there was noted the reduction in pulmonary vascu-
lar resistance and mean pulmonary pressure (p <0.0001), 
an increase in the cardiac index (p<0.0001), a reduction 
in the level of NT-proBNP (p<0.0001) , functional class 
(p=0.003), and Borg index (p=0.002); the time to clini-
cal deterioration increased (p=0.005) (Dumitrascu et al. 
2006). Therapy with riociguat was characterized by good 
tolerability. The effectiveness of the treatment persisted 
with prolonged follow-up in the PATENT-2 study. After a 
year of follow-up, the average value of DT6MX changed 
by 51±74 m, WHO functional class increased in 33% of 
patients, stabilization of PC was observed in 61% and de-
terioration - in 6% of patients compared to the initial point 
of PATENT-1 study.
Riociguat is an oral stimulator of the NO s-receptor 
receptor, which demonstrated vasodilating and anti-remo-
deling properties in preclinical studies.
Further research is needed, but riociguat can be con-
sidered a new option for LH therapy included in patients 
with CTEPH (Kim 2010).
Serotonin antagonists
Serotonin can affect the smooth muscles of the vessels 
in two opposite directions. It causes the release of vaso-
dilator mediators (NO, prostacyclin) in intact endotheli-
al cells, and with direct action on the smooth muscles of 
the vessels causes a vasoconstrictor effect (MacLean and 
Dempsie 2010).
Serotonin is one of the most active BASs affecting va-
rious functions of bronchi and pulmonary parenchyma. 
When released in the aggregation of platelets, serotonin 
at threshold and subthreshold doses increases the vaso-
constrictor effect of other mediators (norepinephrine, 
thromboxane A2, prostaglandin F2a, angiotensin), and 
also increases blood viscosity, affecting red blood cells 
and leukocytes. The pressure reaction is mediated by 
5-hydroxytryptamine 2 (5-OT2) receptors of blood ves-
sels, especially with damage to the endothelium, and sti-
mulation of 5-O2 receptors on platelet membranes leads 
to their activation and aggregation. These changes, medi-
ated by serotonin, occur throughout the body, but the role 
of serotonin in lung pathology is particularly great: 90% 
of unmetabolized serotonin is contained in electron-dense 
granules of platelets, whose task is the vascular bed of 
the lungs, and pulmonary endothelium is the main site of 
active metabolism of serotonin. In patients with PAH, an 
increased serotonin level, a decreased excretion of 5-hy-
droxyindoleacetic acid in the urine and a decreased acti-
vity of serotonin monoamine oxidase were found, indica-
ting a disturbance in the metabolism of serotonin, while 
a decrease in its inactivation is considered one of the ear-
liest criteria for damage to the pulmonary endothelium.
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Currently, both serotonin receptor antagonists and 
serotonin-transporter inhibitors are considered to test the 
relevance of this new therapeutic strategy, specifically di-
rected against the proliferation of pulmonary vessels.
Inhibitors of phosphodiesterase-1
Phosphodiesterases (PDEs) are important enzymes that 
hydrolyse the cyclic nucleotide 3’5’-cyclic monosilica-
te alanosine (cAMP) and 3’5’-cyclic guanosine monop-
hosphate (cGMP) to their inactive 5’-monophosphates. 
Because of their key role in intracellular signaling, they 
are currently of considerable interest as therapeutic targets 
for a wide range of diseases, including PAH. An increased 
level of intracellular cAMP inhibits the activity of immu-
ne and inflammatory cells, and an increase in both cAMP 
and cGMP results in relaxation of smooth muscles. cAMP 
may play an additional role in modulating hypertrophy of 
smooth muscle and hyperplasia, as it has cytostatic effects 
in many types of cells and has an inhibitory effect on the 
proliferation of smooth airway muscles.
PDE1 makes up more than 35% of the cyclic nucleo-
tide hydrolytic activity in the smooth muscle of human 
respiratory tract, and it is involved in the proliferati-
on of human smooth muscle (Murray et al. 2007). It is 
not known whether it participates in the proliferation of 
smooth muscles of the airways, but if so, PDE1 inhibitors 
may be useful in the treatment of respiratory remodeling 
in PAHs of different genesis.
VIP (vasoactive intestinal peptide), a neurotransmit-
ter of the non-adrenergic nervous system, is described 
as a neuroendocrine mediator, which plays an important 
role in the metabolism of water and electrolytes in the 
intestine. In addition, the vasoactive intestinal peptide 
acts as a potent systemic vasodilator and reduces pul-
monary artery pressure and pulmonary vascular resistan-
ce in monocrotalin-induced pulmonary hypertension in 
rabbits; it inhibits platelet activation and smooth mus-
cle cell proliferation. Recently, it has been shown that 
the vasoactive intestinal peptide prevents experimen-
tally induced arthritis in mice. These biological effects 
are mediated by specific VIP receptors – VPAC-1 and 
VPAC-2, localized on the surface of the cell membrane. 
The VPAC receptors are found on the breathable epit-
helium, on the macrophages surrounding the capillaries, 
and in the subintima of the pulmonary arteries and veins. 
Stimulation of the VPAC receptors leads to the activati-
on of cAMP and cGMP systems, which, as it has been 
shown, mediate the action of prostacyclins, NO, phosp-
hodiesterase inhibitors in the treatment of pulmonary 
hypertension (Petkov et al. 2003). The use of vasoactive 
intestinal peptide as a therapeutic agent in primary pul-
monary hypertension led to a significant improvement in 
hemodynamic and prognostic parameters of the disease 
without side effects. The vasoactive intestinal peptide 
takes part in the innervation of the respiratory tract. The 
significance of the dysfunction of VIPergic innervation 
in the pathogenesis of obstructive pathology is currently 
being debated. However, there is a hypothesis about the 
role of the decreased biological activity of the vasoactive 
intestinal peptide in the mechanisms of development of 
bronchial asthma.
It is likely that the dysfunction in the system of this 
peptide may occur again due to the inflammatory process 
in the airways, accompanied by an increase in the level 
and activity of inflammatory cells – neutrophils, eosinop-
hils, mast cells that are capable of producing various pep-
tidases (eg, tryptase) that destroy the vasoactive intestinal 
peptide. Its increased degradation promotes the formation 
of hyperreactivity of the airways and causes reflex bron-
chospasm in patients with obstructive pathology.
Prostanoids are analogues of prostacyclin. Prostacy-
cline is produced by endothelial cells, induces vasodila-
tion and is a potent inhibitor of platelet aggregation. Its 
synthesis is reduced in patients with PAH. For the treat-
ment, drugs with a short half-life, such as epoprostenol, 
treprostinil and iloprost, are used.
Prostanoids are a promising group of drugs for the treat-
ment of pulmonary arterial hypertension, since they have 
not only vasodilating, but also antiplatelet and antiprolif-
erative effects. Therefore, it seems logical to use prostacy-
clin and its analogs to treat patients with various forms of 
PAH. Prostacyclin has a very short-term effect. Its half-life 
in the blood plasma is about 1-2 minutes. Inactivation of 
the drug occurs in the liver. With intravenous administra-
tion, prostacyclin expands not only pulmonary, but also 
systemic arteries, so systemic hypotension is possible
Intravenous use of epoprostenol improves hemody-
namic parameters and functional performance in patients 
with PAH (Barst et al. 1996, Higenbottam et al. 1998). 
This is the only treatment that improves survival in idio-
pathic PAH, according to randomized controlled clinical 
trials (Barst et al. 1996). The main limitation to its use is 
that it has a short half-life (3-5 min), and its metabolites 
are stable only for 8 hours. Therefore, it must be adminis-
tered by continuous infusion through an implanted central 
venous catheter. Infusion begins at a dose of 2-4 ng/kg/
min and increases by 1-2 ng/kg/min every 1-2 days. The 
optimal dose for pharmacotherapy varies from 20 to 40 
ng/kg/min. Due to a large number of side effects arising 
from the perfusion of epoprostenol, the drug is used as the 
first line of therapy only in patients with severe disease, 
i.e. FC IV functional class.
Treprostinil is an analogue of epoprostenol with a lon-
ger half-life (58-80 min); the drug is suitable for intrave-
nous, subcutaneous and aerosol administration. The inha-
lation route is suitable for patients with PAH of group 1. 
Treprostinil improves hemodynamic parameters, reduces 
the symptoms of the disease and increases exercise capac-
ity (Benza et al. 2008). Subcutaneous administration of 
treprostinil begins at a dose of 1-2 ng/kg/min, with a grad-
ual increase in the dose to avoid side effects. The optimal 
dose varies from 20 to 80 ng/kg/min. Intravenous use of 
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treprostinil was approved by the FDA in patients with II, 
III and IV functional class of PAH.
Iloprost is an inhaled synthetic analogue of prostacy-
clin. Iloprost has a short half-life and requires frequent 
administration (six to nine times per day) according to 
the individual patient’s need and tolerance of the drug. 
According to randomized controlled clinical trials involv-
ing PAH patients from groups 1 and 4 and the placebo 
group, Iloprost was inhaled (at an average dose of 30 μg 
per day) for 12 weeks (Olschewski et al. 2002). A clinical 
endpoint was achieved in 16.8% of those who had inhaled 
iloprost compared to 4.9% of those who had received pla-
cebo (p=0.007). Tolerance to physical exertion (function-
al class, a 6-minute walk test) was quantitatively assessed. 
Inhaled iloprost is approved by the FDA for patients with 
PAH of III and IV functional classes.
Possibilities for evaluating 
pharmacological correction of 
pulmonary hypertension with new 
compounds in the experiment
An increase in the number of publications on the problem 
of pulmonary hypertension occurred due to a significant 
increase in reports on studying the pharmacological acti-
vity of compounds of new classes and groups as means of 
pharmacological correction of pulmonary hypertension. 
in the experiments on models in laboratory animals.
One of the most common and easily reproducible mod-
els of the pathology under study is a model of monocro-
talin-induced pulmonary hypertension.
Monocrotalin (MCT) is a macrocyclic pyrrolizidine al-
kaloid extracted from Crotalaria spectabilis. A lot of pyr-
rolizidine alkaloids, products of tropical plants of several 
genera, are toxic to mammals.
MCT, administered in large doses (more than 100 mg/
kg, subcutaneously), like many other toxins, causes ne-
crosis of liver cells. However, in low doses (40-60 mg/
kg, subcutaneously), MCT acts selectively on the endo-
thelium of the lung vessels. An increase in the total dose 
of MCT leads to damage to the vessels of the kidneys 
and small intestine. Now it is generally accepted that not 
MCT itself, but its derivative formed in the liver has a 
pneumotoxic action; it may be a dehydrogenated product 
– monocrotaline-pyrrole. When administered to animals, 
MCT-pyrrole has a stronger toxic effect on the lung ves-
sels than MCT; its effective dose is 12-15 times lower than 
that of its predecessor. The metabolite reaches the pulmo-
nary vessels, accumulating in the red blood cells. First of 
all, the MCT metabolite acts on the endothelial cells of the 
pulmonary vessels, causing their inflammation followed 
by remodeling of the vascular wall. Monocrotaline pul-
monary hypertension (MCT-PH) is characterized by the 
formation of thrombi, especially in the postcapillary bed 
and inflammation of the pulmonary veins, which brings 
the model closer to pulmonary veno-occlusive syndrome 
– one of the pathoanatomical manifestations of primary 
PH (Zakharov and Gerasimenya 2013).
For the first time MCT was applied in 1965 to create a 
model of “pulmonary heart”. Before the development of 
hypertrophy and failure of the right heart in rats treated 
with MCT, thrombocytopenia, the clumping of macro-
phages in the adventitia of pulmonary vessels and ede-
ma due to increased permeability of endothelial cells are 
observed. Treatment with MCT suppresses the activity 
of enzyme systems located on the surface of endothelial 
cells of the lung vessels – angiotensin-converting enzyme, 
plasminogen activator, reuptake systems and serotonin 
metabolism. After 3-4 weeks, depending on the dose of 
MCT – 40 or 60 mg/kg, pulmonary hypertension devel-
ops and hypertrophy of the right ventricle of the heart is 
observed (Zakharov and Gerasimenya 2013).
By this time, the inflammatory response is reduced, 
which is a consequence of the toxic effect of MCT. Thus, 
for example, the content of Substance P in the lung tissue 
decreases, which sharply (about 3 times) increases in the 
lungs after a monocrotalin injection.
According to the international medical information da-
tabase PubMed, the monocrotalin model is used in more 
than 400 publications for modeling PH. In its etiology and 
pathophysiological manifestations, pulmonary hyperten-
sion caused by MCT is close to primary pulmonary hy-
pertension in humans.
Conclusion
The average life expectancy of patients with pulmonary 
arterial hypertension between 1981 and 1985 was 2.8 
years. The use of modern approaches to treatment has 
significantly improved the survival of such patients. So, 
among those taking epoprostenol, 5-year survival is 47-
55%, and according to some data it reaches 70%. Patients 
with signs of right ventricular failure have a much shor-
ter life expectancy than those with an isolated increase in 
systolic pressure in the pulmonary artery. About 15% of 
these patients, even those receiving modern therapy, die 
within a year.
Predictors of the unfavorable prognosis are: increased 
right atrial pressure (above 10 mm Hg), low cardiac in-
dex (below 2.1 L/min-m2), low mixed venous oxygen 
saturation (SaO2 less than 63%), 6-minute walking dis-
tance less than 400 m, the preservation of symptoms 
of cardiac failure of FC III-IV, poor physical tolerance, 
pericardial effusion and an increased level of the brain 
natriuretic peptide.
The existing available drugs improve physical perfor-
mance and functional class in patients with PAH. Ran-
domized clinical trials have also showed the improved 
hemodynamic parameters and increased time to clini-
cal deterioration. Although the impact on mortality was 
less pronounced, progress in therapeutic strategies has 
allowed better predictions, especially for patients with 
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PAH. It is likely that combination therapy will become 
the cornerstone of the treatment of idiopathic PAH in the 
future, and the study and introduction of new pharmaco-
logical preparations will become part of the therapeutic 
arsenal to improve the quality of life, to slow down the 
progression of the disease and to improve the survival of 
patients. Future directions are aimed at better description 
of the PAH pathogenesis, which remains incomplete. In-
deed, the pathophysiology and genetics of this disease 
can be a link to new therapies. Although it is clear that 
platelets, fibroblasts and circulating cells are involved in 
the progression of PAH, changes in smooth muscle cells 
of the pulmonary artery and in pulmonary arterial endo-
thelial cells resulting from multiple genetic and acquired 
defects are probably the main cause of the occurrence. 
Accordingly, efforts to develop effective therapeutic strat-
egies should target genes, molecular mechanisms and 
pathogenetic pathways involved in the disease.
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